Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1400ANCILLARY||SWOG||Ancillary Study to Evaluate Patient and Physician Attitudes; Knowledge; and Expectations Related to Return of Genomic Results in Cancer in the SWOG 1400 (S1400) Clinical Trial||Adult CIRB - Late Phase Emphasis|
|ACNS1833||COG||A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)||Pediatric CIRB||Available to Open|
|10050||ETCTN||A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer harboring KRAS G12R Mutations||Adult CIRB - Early Phase Emphasis||Available to Open|
|10015||ETCTN||A Non-Randomized; Open-Label; Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma||Adult CIRB - Early Phase Emphasis||Available to Open|
|NHLBI-MDS||ECOG||The National Myelodysplastic Syndromes (MDS) Study||Cancer Prevention and Control CIRB||Available to Open|
|NRG-GY017||NRG||Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|A231701CD||Alliance||Increasing Socioeconomically Disadvantaged Patients’ Engagement in Breast Cancer Surgery Decision Making Through a Shared Decision Making Intervention||Cancer Prevention and Control CIRB||Available to Open|
|10131||ETCTN||A Phase 1 Study of AZD8186 in Combination with Docetaxel in patients with PTEN mutated or PIK3CB mutated advanced solid tumors, potentially amenable to docetaxel||Adult CIRB - Early Phase Emphasis||Available to Open|
|9706||ETCTN||Randomized phase II study to assess the role of Nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy (REMAIN Trial)||Adult CIRB - Early Phase Emphasis||Available to Open|
|S1007||SWOG||A Phase III; Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes; Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node; Endocrine Responsive Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|